Synthesis, hydroxyl radical production and cytotoxicity of analogues of bleomycin.

[1]  P. Wardman,et al.  Preparative, physico-chemical and cytotoxicity studies of prodrugs activated in hypoxia to give metal-binding analogues of bleomycin , 1999 .

[2]  P. Wardman,et al.  Synthesis and properties of prodrugs activated in hypoxia to give bleomycin analogues. , 1998, Bioorganic & medicinal chemistry letters.

[3]  S. Hecht,et al.  Spectroscopic Investigation of the Metal Ligation and Reactivity of the Ferrous Active Sites of Bleomycin and Bleomycin Derivatives , 1998 .

[4]  Michael Molls,et al.  Blood perfusion and microenvironment of human tumors : implications for clinical radiooncology , 1998 .

[5]  S. McClean,et al.  Bleomycin mimics. Design and synthesis of an acridine derivative whichcleaves DNA in a sequence-neutral manner , 1997 .

[6]  M. Harms-Ringdahl,et al.  H2O2-driven reduction of the Fe3+-quin2 chelate and the subsequent formation of oxidizing species. , 1997, Free radical biology & medicine.

[7]  D. Vanderwall,et al.  BLEOMYCINS : A STRUCTURAL MODEL FOR SPECIFICITY, BINDING, AND DOUBLE STRAND CLEAVAGE , 1996 .

[8]  A. Kassis,et al.  Measurement of hydroxyl radicals catalyzed in the immediate vicinity of DNA by metal-bleomycin complexes. , 1996, Free radical biology & medicine.

[9]  J. Lown,,et al.  Functional Models of the Antitumor Antibiotic Bleomycin , 1995, Current Medicinal Chemistry.

[10]  J. Lown,,et al.  Design, synthesis, and sequence selective DNA cleavage of functional models of bleomycin. 1. Hybrids incorporating a simple offal-complexing moiety of bleomycin and lexitropsin carriers. , 1995, Bioconjugate chemistry.

[11]  S. Hecht,et al.  On the role of the bithiazole moiety in sequence-selective DNA cleavage by Fe.bleomycin. , 1994, The Journal of biological chemistry.

[12]  S. Hecht,et al.  On the Role of Individual Bleomycin Thiazoles in Oxygen Activation and DNA Cleavage , 1992 .

[13]  K. Maeda,et al.  Man-designed bleomycin with altered sequence specificity in DNA cleavage , 1990 .

[14]  R. L. Jones,et al.  The interaction of unfused polyaromatic heterocycles with DNA: intercalation, groove-binding and bleomycin amplification. , 1990, Anti-cancer drug design.

[15]  C. Bailly,et al.  Metal-complexing, DNA-binding and DNA-cleaving properties of a synthetic molecule AMBIGLU, a simplified model for the study of bleomycin , 1989 .

[16]  L. Strekowski,,et al.  Amplification of bleomycin-mediated degradation of DNA by polyamines. , 1988, Anti-cancer drug design.

[17]  L. Strekowski,,et al.  Amplification of bleomycin-mediated degradation of DNA. , 1987, Journal of medicinal chemistry.

[18]  R. McClelland,et al.  Products of reductions of 2-nitroimidazoles , 1987 .

[19]  L. Strekowski,,et al.  Molecular basis for anticancer drug amplification: interaction of phleomycin amplifiers with DNA. , 1986, Journal of medicinal chemistry.

[20]  W. Haseltine,et al.  Structural basis for the deoxyribonucleic acid affinity of bleomycins. , 1982, Biochemistry.

[21]  J. S. Lee,et al.  Review: ethidium fluorescence assays. Part 1. Physicochemical studies. , 1979, Nucleic acids research.

[22]  A. Grollman,et al.  Bleomycin-DNA interactions: fluorescence and proton magnetic resonance studies. , 1977, Biochemistry.

[23]  G. Trout.  Synthesis of some histidine analogs and their effect on the growth of a histidine-requiring mutant of Leuconostoc mesenteroides. , 1972, Journal of medicinal chemistry.

[24]  K. Ninomiya,et al.  Diphenylphosphoryl azide. A new convenient reagent for a modified Curtus reaction and for the peptide synthesis. , 1972, Journal of the American Chemical Society.